A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer (Q46799300)

25 December 2017

meta-analysis

0 references

title

A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer (English)

1 reference

25 December 2017

0 references

0 references

1 reference

7

1 reference

25 December 2017

author name string

Zsuzsanna Mihály

1

1 reference

25 December 2017

Máté Kormos

2

1 reference

25 December 2017

András Lánczky

3

1 reference

25 December 2017

Magdolna Dank

4

1 reference

25 December 2017

Jan Budczies

5

1 reference

25 December 2017

Marcell A Szász

6

1 reference

25 December 2017

language of work or name

English

0 references

publication date

9 July 2013

1 reference

25 December 2017

Breast Cancer Research and Treatment

published in

1 reference

25 December 2017

volume

140

1 reference

25 December 2017

issue

2

1 reference

25 December 2017

page(s)

219-232

1 reference

25 December 2017

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

cites work

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Combinatorial biomarker expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Pharmacogenetics of endocrine therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Jetset: selecting the optimal microarray probe set to represent a gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

beadarray: R classes and methods for Illumina bead-based data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

A comparison of normalization methods for high density oligonucleotide array data based on variance and bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Biological determinants of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Tubulin-Independent Tau in Alzheimers Disease and Cancer: Implications for Disease Pathogenesis and Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

A role for the HOXB7 homeodomain protein in DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Estrogen receptor β causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Endocrine response and resistance in breast cancer: a role for the transcription factor Fos.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Resistance to endocrine therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

RNA-Seq: a revolutionary tool for transcriptomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Genomic index of sensitivity to endocrine therapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Bad expression predicts outcome in patients treated with tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Association of Double-Positive FOXA1 and FOXP1 Immunoreactivities with Favorable Prognosis of Tamoxifen-Treated Breast Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

High Expression of Sphingosine 1-Phosphate Receptors, S1P1 and S1P3, Sphingosine Kinase 1, and Extracellular Signal-Regulated Kinase-1/2 Is Associated with Development of Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

AIB1 is a predictive factor for tamoxifen response in premenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

SpliceArray profiling of breast cancer reveals a novel variant of NCOR2/SMRT that is associated with tamoxifen resistance and control of ERα transcriptional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2622-Y

10.1007/S10549-013-2622-Y

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017